Skip to main content
Toggle navigation
Login
Search
Home
Tweets by IDWeek 2023
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Marc Engelhardt, MD
Dr.
Basilea Pharmaceutica International Ltd., Allschwil, Switzerland, Switzerland
Poster(s):
(1699) Safety and Outcomes of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Patients
Friday, October 13, 2023
12:15 PM – 1:30 PM
US ET
(2530) Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2531) Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with
Staphylococcus aureus
Bacteremia (SAB)
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2532) Pharmacokinetic-Pharmacodynamic Analyses for Ceftobiprole Efficacy Based on Phase 3 Data from Patients with
Staphylococcus aureus
Bacteremia
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2561) Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2785) Characterization of Methicillin-resistant
Staphylococcus aureus
Bloodstream Isolates Recovered from Patients Enrolled in a Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole for Treatment of Bacteremia, Including Infective Endocarditis
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET